Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts

Federal Circuit Affirms Invalidation Of Two Amgen Patents

The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.

businessmen moving chess pieces on board of worldwide politics — Repatha and Praluent will continue to battle for US market share • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. is the victor in a long-running US patent dispute with Amgen, Inc. over patents pertaining to antibody therapies targeting PCSK9 for the reduction of LDL cholesterol in the treatment of hypercholesterolemia. Regeneron and its partner Sanofi continue the commercial battle for market share, however, with Amgen’s PCSK9 inhibitor Repatha (evolocumab) generating hundreds of millions of dollars more in global sales than their product Praluent (alirocumab).

Regeneron announced on 11 February that the US Court of Appeals for the Federal Circuit upheld a US District Court...